Clinical Evaluation of Individualized and Navigated Microsecond Pulsing Laser for Acute Central Serous Chorioretinopathy

Abstract

BACKGROUND AND OBJECTIVE: A computational model has predicted parameters for using a navigated microsecond pulsing laser system to treat central serous chorioretinopathy (CSC). PATIENTS AND METHODS: A prospective, single-center, interventional case series was conducted for patients with acute CSC who were enrolled following screening and informed consent. Treatment involved laser pulse duration of 50 μs, 2.4% Duty Cycle, 100 μm spot size, and 10 ms pulse duration. RESULTS: Average best-corrected visual acuity (decimal) of 12 patients improved from 0.86 ± 0.03 at baseline to 0.97 ± 0.01 at 3 months. Baseline central retinal thickness decreased from 452.58 μm ± 24.53 μm at baseline to 249.25 μm ± 2.92 μm at 3 months. Retinal sensitivity improved from 24.1 dB ± 1.09 dB at baseline to 28.98 dB ± 0.23 dB at 3 months. In all cases, subretinal fluid was resorbed. CONCLUSION: The parameter sets derived from the computer model can be applied safely and effectively for CSC treatment using the navigated microsecond pulsing laser system. [ Ophthalmic Surg Lasers Imaging Retina . 2020;51:512–520.]

Influence of Retinal Microsecond Pulse Laser Treatment in Central Serous Chorioretinopathy: A Short-Term Optical Coherence Tomography Angiography Study

“…Furthermore, it has been shown to increase the antioxidative potential [ 17 , 18 ] and to reduce the thickness of the Bruch’s membrane in an age-related macular degeneration (AMD) mice model [ 19 , 20 , 21 , 22 ]. Thus, sublethal RPE thermal treatment gained increasing attention as a new therapeutic option for different macular disorders, such as CSC, diabetic macular edema and AMD [ 20 , 23 ]. In particular, the PLACE trial and a recent meta-analysis demonstrated that SML may be considered as a competitive alternative to PDT for treating chronic CSC, and as the first-line treatment of chronic CSC [ 24 , 25 ].…”